The European Commission

R&D

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

News

Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.